Sjogren's Syndrome | Current Treatment | Detailed, Expanded Analysis (US)

Publish date: January 2019

Login to access report

Coming Soon – August 2019


The primary goals of treatment of Sjögren’s syndrome (SS) are to relieve the hallmark sicca symptoms and minimize the impact and progression of systemic disease manifestations. Although an array of symptomatic therapies are available to help manage these symptoms, no medication is approved to treat the underlying autoimmune processes in SS. As such, clinicians rely on marketed therapies used to treat other autoimmune diseases, despite the limited availability of clinical data supporting their use. This content will quantitatively explore the current treatment of SS as marketed biologics and novel agents advance in the pipeline.


  • Which systemic disease manifestations are most common among the patient populations of surveyed rheumatologists?
  • How do rheumatologists approach the management of primary and secondary SS patients?
  • Which SS patients receive biologics (e.g., GlaxoSmithKline’s Benlysta, Bristol-Myers Squibb’s Orencia, Roche/Genentech’s Actemra) and in which line(s) of therapy? What factors drive movement of SS patients through lines of therapy?
  • Which drugs are the patient-share leaders in SS? How are key conventional oral immunosuppressants positioned in surveyed physicians’ treatment algorithms?
  • What are the most influential drivers of treatment selection in SS?


Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Detailed, Expanded Analysis (US)
    • Coming Soon
      • Coming Soon

Author(s): Michael Breen, PhD

Michael is a business insights analyst on the Infectious, Niche, and Rare Diseases team. He has authored reports on cystic fibrosis, nonalcoholic steatohepatitis, vaccines, and  respiratory syncytial virus, and will author a report on cytomegalovirus. He also provides coverage for Decision Resources’ Company & Drug Insights covering anti-infectives, vaccines, and transplant therapy areas. Michael received his Bachelor’s degree from Hunter College with a dual major in biology and biochemistry. He received his in biochemistry from Boston University School of Medicine. His postdoctoral research was carried out at Brigham and Women’s Hospital/Harvard Medical School, with a focus on identifying novel pathways regulating thermogenesis in search of a therapeutic for obesity and diabetes.